Delcath Systems to Present at LD Micro Virtual Investor Conference on June 10, 2021, at 2:30pm ET
June 03 2021 - 8:00AM
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional
oncology company focused on the treatment of rare primary and
metastatic cancers of the liver, today announced that management
will present at:
LD Micro Virtual Investor ConferenceDate: June
10, 2021Time: 2:30 p.m. ET – Track
1Webcast: https://ldmicrojune2021.mysequire.com
A live audio webcast and archive of the event presentation will
be available using the webcast link above. For more information on
the LD Micro Invitational XI, or to register for the event, please
visit https://ldmicrojune2021.mysequire.com.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
Our investigational product, HEPZATO KIT (melphalan hydrochloride
for injection/hepatic delivery system), is designed to administer
high-dose chemotherapy to the liver while controlling systemic
exposure and associated side effects. HEPZATO KIT has not been
approved by the U.S. Food & Drug Administration (FDA) for sale
in the U.S. In Europe, our system is marketed under the trade name
Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT)
and has been CE Marked and used at major medical centers to treat a
wide range of cancers of the liver. CHEMOSAT is being marketed
under an exclusive licensing agreement with medac GmbH, a privately
held multi-national pharmaceutical company headquartered in Germany
that specializes in the treatment and diagnosis of oncological,
urological and autoimmune diseases.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
Hayden IR
James
Carbonara (646)-755-7412 james@haydenir.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jul 2023 to Jul 2024